NBIX News and Press, Neurocrine Biosciences Inc. From 09/08/21

BURNABY, British Columbia, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that its collaboration to develop treatments for epilepsy with Neurocrine Biosciences, Inc. (Nasdaq: NBIX) achieved a regula...

Neurocrine posted better than expected sales in the second quarter, with a much-needed beat for Ingrezza sales, but the resurgence of COVID-19 infections threatens to unravel that progress. Ingrezza prescriptions really depend upon face-to-face visits with prescribing physicians, and ...

Neurocrine Biosciences (NBIX -3.2%) trading lower in morning hours after Canaccord Genuity lowered the recommendation to hold from buy, citing the need for a better entry point on uncertain sales prospects for the company’s lead revenue generator Ingrezza. While Neurocrine (NASDAQ:NBIX...

Neurocrine Biosciences Announces Completion of Enrollment in Phase 3 KINECT-HD Study Evaluating Valbenazine for Chorea in Huntington Disease - Top-Line Readout of Clinical Study Results Anticipated by the End of 2021 - Initiating Expanded Enrollment to New Participants in Op...

The following slide deck was published by Neurocrine Biosciences, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Neurocrine Biosciences, Inc. 2021 Q2 - Results - Earnings Call Presentation

Image source: The Motley Fool. Neurocrine Biosciences, inc (NASDAQ: NBIX) Q2 2021 Earnings Call Aug 3, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Neurocrine Biosciences, inc (NBIX) Q2 2021 Earnings Call Transcr...

Neurocrine Biosciences, Inc. (NBIX) Q2 2021 Results Conference Call August 03, 2021 04:30 PM ET Company Participants Todd Tushla - VP, IR Kevin Gorman - CEO Matt Abernethy - CFO Eiry Roberts - Chief Medical Officer Eric Benevich - Chief Commercial Officer Kyle Gano - Chief Business Developmen...

Neurocrine Biosciences (NASDAQ:NBIX): Q2 Non-GAAP EPS of $0.63 misses by $0.13; GAAP EPS of $0.43 misses by $0.06. Revenue of $288.9M (-4.5% Y/Y) beats by $15.01M. Press Release For further details see: Neurocrine Biosciences EPS misses by $0.13, beats on revenue

Neurocrine Biosciences Reports Second Quarter 2021 Financial Results INGREZZA® (valbenazine) Second Quarter 2021 Net Product Sales of $265 Million with Approximately 48,900 Total Prescriptions Phase 3 Registrational Program of Valbenazine for the Treatment of Chorea Ass...

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2021 Financial Results Conference Call and Webcast Scheduled for Tuesday, August 3 PR Newswire SAN DIEGO , July 19, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: ...